Federal Register #FDA-2026-N-5057

FDA Public Meeting: Patient-Focused Drug Development for Nonhealing Chronic Wounds

This opportunity is an FDA-hosted public meeting focused on patient perspectives for nonhealing chronic wounds. - Government Buyer: - Department of Health and Human Services (HHS) - Food and Drug Administration (FDA) - Purpose: - Public meeting to gather patient and care partner input on the impact of nonhealing chronic wounds, treatment approaches, and clinical trial participation - Input will inform future drug development and regulatory decisions - Products/Services Requested: - No products or services are being procured - No OEMs or vendors are mentioned - Unique/Notable Requirements: - The meeting is hybrid (in-person at FDA White Oak Campus and virtual) - Public comments are solicited to guide future policy - Place of Performance: - FDA White Oak Campus, Silver Spring, MD (in-person) - Virtual attendance option

Description

The Food and Drug Administration (FDA) is announcing a public meeting titled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The meeting aims to gather patient perspectives on the impact of nonhealing chronic wounds, treatment approaches, factors in treatment selection, and participation in clinical trials. It will be held in person and virtually on August 25, 2026. Comments on the meeting are requested and must be submitted by October 26, 2026.

View original listing